November 20, 2026
Source: drugdu
35

On November 19, The United Laboratories (03933) announced that China’s National Medical Products Administration had granted implicit clinical trial clearance for UBT48128 tablets, a Class 1 innovative drug developed by its wholly owned subsidiary, United Biotechnology in Zhuhai Hengqin.
UBT48128 is an investigational small-molecule GLP-1 receptor agonist intended for once-daily oral use. It is designed to lower blood glucose and body weight as a potential treatment option for people with overweight or obesity. The candidate previously received US FDA clearance for clinical trials on August 11, 2026.
Source: http://finance.eastmoney.com/a/202611203935753843.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.